Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the year ending December 31, 2022, the company expects net profit attributable to shareholders of the listed company of RMB 617.00 million to RMB 773.00 million, increase as compared with the corresponding period: 156.24% to 221.03% and basic earnings per share of RMB 0.4205 per share to RMB 0.5268 per share.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.78 CNY | +1.03% |
|
+18.26% | -16.62% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-16.62% | 177.85Cr | |
+25.40% | 4.53TCr | |
+38.38% | 2.43TCr | |
+25.83% | 1.65TCr | |
+21.19% | 1.46TCr | |
+71.91% | 1.43TCr | |
-0.05% | 678.76Cr | |
-11.63% | 656.86Cr | |
+15.08% | 576.04Cr | |
-8.87% | 572.55Cr |
- Stock Market
- Equities
- 002399 Stock
- News Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022